TY - JOUR
T1 - Hepatocellular Carcinoma
AU - Marrero, Jorge A.
AU - Pelletier, Shawn
PY - 2006/5
Y1 - 2006/5
N2 - It is expected that the number of patients who have HCC will continue to increase over the next 2 decades. Currently, most patients who have HCC present with advanced disease, and the overall survival has improved minimally over the last 20 years, making early detection crucial. Patients who have cirrhosis are at the highest risk for developing HCC and constitute the population in which surveillance should be performed. AFP and ultrasound are the major means of surveillance, although evidence of their efficacy is lacking. Once HCC is diagnosed, staging is critical to determine prognosis and the treatment plan. The BCLC is the preferred method for staging and for guiding therapy. Resection, transplantation, and percutaneous ablation are considered curative because of their excellent 5-year survival rates. Currently, there is no standard therapy for advanced HCC.
AB - It is expected that the number of patients who have HCC will continue to increase over the next 2 decades. Currently, most patients who have HCC present with advanced disease, and the overall survival has improved minimally over the last 20 years, making early detection crucial. Patients who have cirrhosis are at the highest risk for developing HCC and constitute the population in which surveillance should be performed. AFP and ultrasound are the major means of surveillance, although evidence of their efficacy is lacking. Once HCC is diagnosed, staging is critical to determine prognosis and the treatment plan. The BCLC is the preferred method for staging and for guiding therapy. Resection, transplantation, and percutaneous ablation are considered curative because of their excellent 5-year survival rates. Currently, there is no standard therapy for advanced HCC.
UR - http://www.scopus.com/inward/record.url?scp=33846263092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846263092&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2006.05.012
DO - 10.1016/j.cld.2006.05.012
M3 - Review article
C2 - 16971265
AN - SCOPUS:33846263092
SN - 1089-3261
VL - 10
SP - 339
EP - 351
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
IS - 2
ER -